with overt metastatic disease using combination cisplatin-based chemotherapy. 8, 9 Therefore, it made sense to incorporate therapy when the disease burden may have been lower and the potential benefit greater. Because of the encouraging responses seen in primary tumors in patients with overt metastasis, chemotherapy was evaluated preoperatively in patients undergoing cystectomy, in whom a significant 5-year survival advantage (54% vs. 12%) was noted in those who had been down-staged to less than pT2 disease and served as an impetus for further study. 7, 10, 11 
Perioperative Chemotherapy Trial Data
Perioperative chemotherapy has been studied in patients with muscle-invasive bladder cancer undergoing cystectomy in both the neoadjuvant and adjuvant setting; however, interpretation of the results has been problematic because of poor trial design, poor patient accrual, inferior chemotherapy regimens, and poor trial execution in many of the trials. [11] [12] [13] [14] [15] [16] [17] [18] Therefore, meta-analyses of these randomized trials have also been performed to provide stronger evidence to support the role of perioperative chemotherapy in patients with invasive bladder cancer. [15] [16] [17] [18] A recent update of the meta-analyses of 11 randomized control trials (RCTs) involving 3005 patients (98% of patients from all known eligible trials) evaluated the usefulness of neoadjuvant platinum-based combination chemotherapy. This study confirmed a modest survival benefit, with an approximate 5% absolute improvement in overall survival at 5 years (P = .003) consistent across all patient subgroups, irrespective of the type of local treatment, and a 14% reduction in the risk for death (Fig. 1) . 17 In addition, the authors found a significant disease-free survival benefit associated with platinum-based combination chemotherapy (hazard ratio [HR], 0.78; 95% CI, 0.71-0.86; P < .0001), equivalent to a 9% absolute improvement at 5 years.
Evidence supporting adjuvant chemotherapy is less clear because of the small size and limited quality of trial data available, but it seems to be favored by clinicians, most likely because of the ability to make treatment decisions based on pathologic rather than clinical staging.
14,18-20 A meta-analysis based on 491 Figure 1 Meta-analyses of randomized controlled trials for neoadjuvant chemotherapy in invasive bladder cancer. HR plot for overall survival. Each trial is represented by a square, the center of which gives the HR for that trial. Size of the square is proportional to the information in that trial. Ends of horizontal bars denote the 99% CI and inner bars mark the 95% CI. Trials are ordered chronologically by start date (oldest first). The black diamond gives the overall HR for the combined results of all trials; the center denotes the HR, the extremities the 95% CI. The shaded diamonds denote the HRs for the trial groups; the center denotes the HR, the extremities the 95% CI. Single-agent platinum: heterogeneity Chi 2 = 1.11 (P = .57); inconsistency I 2 = 0%. Platinum-based combinations: heterogeneity Chi 2 = 2.81 (P = .83); inconsistency I 2 = 0. patients from 6 RCTs, representing 90% of all patients from platinum-based combination chemotherapy trials and 66% from all eligible trials, reported a 25% (overall HR, 0.75; 95% CI, 0.60-0.96; P = .019) relative reduction in the risk of death with chemotherapy equivalent to a 9% (95% CI, 1%-16%) absolute improvement in survival at 3 years (Fig. 2) . 18 Again, when considering only cisplatin-based combination chemotherapy trials, the absolute improvement in survival at 3 years increases to 11% (95% CI, 3%-18%). 18 Until recently, the influence that quality of surgery may have on the outcomes of perioperative chemotherapy trials was not considered when analyzing trial outcomes or in trial design. Retrospective analyses of single-institution cystectomy series and from the Surveillance, Epidemiology and End Results (SEER) Program cancer registry indicate that overall survival with cystectomy improves as the number of nodes examined increases and that the number of nodes removed can be used as a surrogate measure of the quality of lymphadenectomy. [21] [22] [23] Findings from a recent retrospective subset analysis of the randomized cooperative Intergroup-0080 trial evaluating the influence of surgical factors on outcomes after adjusting for pathologic and chemotherapy treatment factors further supports the importance surgical technique has on outcomes. 24, 25 The authors examined surgical factors, including soft tissue surgical margins, number of nodes removed, and surgeon experience, as well as institution type, accounting for other patient, pathologic, and treatment variables. In a multivariate analysis of surgical predictors for postcystectomy survival that adjusted for other covariates (treatment type, age, pathologic stage, and node status), surgical soft tissue margin status (positive vs. negative; P = .0007) and number of nodes removed (< 10 vs. > 10; P = .0001) were the strongest independent surgical predictors of local recurrence and overall survival ( Table 1) . 25 Unsurprisingly, soft tissue surgical margin status and the extent of the node dissection as expressed by the number of nodes removed were associated with each other, and a positive surgical margin was associated with fewer nodes removed (P = .01 from 2 test). 25 These findings, although not conclusive, suggest that the quality of surgery significantly influences bladder cancer outcomes, and that chemotherapy is unlikely to compensate for poorly performed surgery.
Integration of Perioperative Chemotherapy
Most clinicians agree that current evidence supports the use of perioperative chemotherapy in patients with muscle-invasive bladder cancer; however, debate continues over the optimal timing with cystectomy. Tables 2 and 3 summarize the common reasons for using neoadjuvant versus adjuvant therapy and the supporting data for each. Although more supportive data exists for the use of neoadjuvant therapy, a recent study using the National Cancer Data Base indicates that in the United States most perioperative chemotherapy is given in the adjuvant setting. 19 Proponents for adjuvant therapy argue that neoadjuvant chemotherapy confers risk for disease progression because 1) it delays local therapy (surgery) for the primary tumor, 2) it increases the difficulty of the surgery possibly increasing morbidity, 3) patients may be overtreated unnecessarily (high cure rate for ≤ pT2N0 disease with surgery alone), 4) the toxicity of the therapy outweighs the benefit, and 5) adjuvant therapy is equally as effective. 20, 26 However, data from neoadjuvant RCTs have not shown a detrimental effect associated with delayed surgery, and comparisons of data on delay in time to treatment of greater than 12 weeks are inappropriate because patients were not undergoing any treatment before surgery in those studies. 7, 12, 14, 16, 18 In a recent study comparing a delay of greater than versus less than 3 months from transurethral resection to cystectomy, Nielsen et al. 27 were unable to show a significant association among risk for extravesical disease, nodal status, disease recurrence, and overall or diseasespecific survival.
Furthermore, a trial reported by Millikan et al. 28 randomizing 140 patients to 2 chemotherapy cycles before surgery and 3 after surgery versus 5 cycles after surgery showed that 97% of patients in the neoadjuvant arm underwent at least 2 cycles of therapy compared with only 77% of patients in the adjuvant arm. This finding is consistent with reports from other RCTs evaluating adjuvant therapy, indicating that only 50% to 70% of patients actually underwent the planned 3 or 4 cycles of adjuvant therapy, compared with 87% to 97% in the neoadjuvant setting. 7, 18 In addition, an opposing theoretical argument would be that a delay in initiation of adjuvant therapy carries an equal risk for growth of distant micrometastasis while awaiting the initiation of systemic therapy.
In the trial by Millikan et al., 28 although the investigators planned to administer adjuvant therapy within 84 days, it was actually initiated within an average of 103 to 114 days because of delays in postoperative recovery. Various reasons have been cited for delaying adjuvant therapy, including delayed recovery from surgery, renal insufficiency, patient refusal, surgical complications, poor performance status, psychological distress, and old age. 7 A recent retrospective review of Memorial Hospital's surgical experience estimates that up to 30% of patients undergoing a radical cystectomy may experience a complication within the 90 days during which adjuvant therapy would be started, potentially delaying or preventing its initiation. 29 Despite speculation that neoadjuvant chemotherapy may increase the difficulty of surgery, and thereby surgical morbidity, no significant differences in surgical morbidity were reported in the neoadjuvant RCTs or other trials. [14] [15] [16] [17] 24, 28 In the Intergroup trial, the planned cystectomy was performed in 82% of patients in the combined-treatment arm versus 81% in the surgery-alone arm. 24 Moreover, significant down-staging of tumors was achieved with an overall pT0 rate of 38%, including 50% of patients with an initial clinical stage T2 and 30% of those with an initial clinical stage of T3 or T4a. A similar pT0 rate of 33% was achieved in the largest single study of neoadjuvant chemotherapy (N = 976). 11, 17, 18 However, the high cure rates for surgery alone with pT2 disease (57%-79%) in contemporary surgical series and the inaccuracies of clinical staging have still led many urologists to favor adjuvant therapy in only those considered at high risk for recurrence (≥ pT3 and/or N+) with surgery alone. 30 On the other hand, a relapse rate of 30% to 40% with surgery alone is not insignificant, nor is a potential improvement in median survival of 30 months for those with pT2 disease as seen in the neoadjuvant therapy arm in the Intergroup trial. 7, 24 The high rate of clinical understaging, even in experienced hands, must also be considered. 24, 30 Millikan et al. 28 reported only a 40% correlation between clinical and pathologic stage, with 61% of patients upstaged to pT3 and/or N+ disease. This occurred despite 2 independent urologists corroborating on the clinical stage.
Lastly, chemotherapy given in the neoadjuvant setting allows assessment of tumor response, which helps determine the effectiveness of chemotherapy, future development of molecular markers predicting response and chemoresistance, and development of new chemotherapeutic agents; and is not possible with adjuvant therapy. Proponents of adjuvant therapy, however, would argue that because of the inaccuracies of clinical staging, some patients will undergo neoadjuvant therapy unnecessarily. Similarly, adjuvant therapy carries the risk for continued treatment with an ineffective regimen because no marker lesion is present to assess for response, whereas neoadjuvant therapy allows for an interim assessment of response and a change in therapy, or earlier surgical intervention if the tumor is chemoresistant.
Conclusion: Strategy Versus Reality
The reality today is that perioperative chemotherapy, and particularly neoadjuvant therapy, is substantially underused despite evidence showing a survival benefit, indicating that the strategy has not been well implemented. 7, 19, 30 The best evidentiary data support chemotherapy in the neoadjuvant setting for muscleinvasive disease. 7, [11] [12] [13] [14] [15] [16] [17] Experts also know that patients are more likely to undergo at least 3 cycles (therapeutic) of therapy when given in the neoadjuvant setting compared with the adjuvant setting. 7, 28 However, although most would agree that patients at the highest risk for recurrence (e.g., those with pT3 and/or N+ disease) should undergo perioperative chemotherapy, a recent review of the National Cancer Data Base evaluating the strategy of perioperative chemotherapy in patients with stage III bladder cancer showed that only 11.6% underwent any perioperative chemotherapy, and most in the adjuvant setting. 19 Furthermore, an analysis of the patterns of care and outcomes for muscle-invasive bladder cancer in the Medicare population using the SEER program data indicates that surgical standards are not being met either. Only 39% of patients with muscle-invasive disease underwent radical cystectomy within 6 months of diagnosis, most either without node dissections or with inadequate dissections, which clearly impacts survival. 23, 25, 31 Although patient comorbidities may account for some underuse of chemotherapy and cystectomy, it is unlikely they would result in 88% of patients with stage III bladder cancer failing to undergo perioperative chemotherapy and only 39% of patients undergoing cystectomy as definitive treatment. 19, 23, 31 A better understanding is needed of why chemotherapy and cystectomy are underused in the treatment of invasive bladder cancer (i.e., patient or physician preferences, referral patterns, access to care, comorbidities, fund of knowledge). In the interim, using neoadjuvant therapy to treat those with invasive bladder cancer (≥ cT2) would make more sense to allow study of gene expression profiles for chemoresistance and response to expedite individualized risk-adjusted therapy for all patients.
